Point-of-Care Adipose-derived Cells for Hair Growth
Launched by UNIVERSITY OF FLORIDA · Mar 31, 2016
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
This is a prospective, non-randomized, non-blinded, interventional, consecutive series, single site study to determine initial safety and feasibility of a single injection of autologous adipose-derived SVF cells for the treatment of alopecia.
Up to 8 subjects who have been diagnosed with androgenetic alopecia will be asked to participate. Before the procedure the density (number of hairs per square centimeter) and thickness (mm) of the hair will be measured and compared to the same measurements after the procedure. All adverse events will be recorded and evaluated for severity.
Subjects w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects will be in good health (ASA Class I-II) with a BMI \< 35.
- • Must have at least a 2cm x 2cm spot on the scalp which shows evidence of alopecia without scarring or traumatic injury
- • Able and willing to make the required study visits.
- • Able and willing to give consent and follow study instructions.
- • Must speak, read and understand English
- Exclusion Criteria:
- • History of bleeding disorders, anticoagulation therapy that cannot be stopped 14 days prior to injection
- • Allergic to lidocaine, epinephrine, Vancomycin, cephalexins, cephalosporins, penicillins, chlorhexidine gluconate, or tattoo ink
- • Individuals with a propensity for keloids
- • Individuals with diminished decision-making capacity will not be included in this research study.
- • Current use of anti-inflammatory or anticoagulation medications that affect bleeding or are for bleeding disorders. These include: Plavix, Warfarin (Coumadin, Jantoven, Marfarin).
- • Use of concomitant treatments to improve hair growth, including topical medications, oral medications, meso-therapy, non-ablative fractional laser treatment, low-level laser therapy, interfollicular PRP injection and hair transplantation within the preceding 6 months.
- • Smoking and other tobacco use.
- • Pregnancy or lactating period for females
About University Of Florida
The University of Florida, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials. With a focus on enhancing patient outcomes and exploring new therapeutic avenues, the university leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct rigorous research across a variety of medical fields. Committed to ethical standards and patient safety, the University of Florida fosters collaboration among researchers, healthcare professionals, and community stakeholders to translate scientific discoveries into impactful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gainesville, Florida, United States
Patients applied
Trial Officials
Adam Katz, MD
Principal Investigator
University of Florida
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials